Hepatitis B - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 386 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatitis B - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hepatitis B - Pipeline Review, H1 2016', provides an overview of the Hepatitis B pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatitis B
- The report reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hepatitis B therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis B therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hepatitis B


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hepatitis B
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 7
Hepatitis B Overview 8
Therapeutics Development 9
Hepatitis B - Therapeutics under Development by Companies 11
Hepatitis B - Therapeutics under Investigation by Universities/Institutes 18
Hepatitis B - Pipeline Products Glance 19
Hepatitis B - Products under Development by Companies 23
Hepatitis B - Products under Investigation by Universities/Institutes 32
Hepatitis B - Companies Involved in Therapeutics Development 33
Hepatitis B - Therapeutics Assessment 109
Drug Profiles 121
Hepatitis B - Recent Pipeline Updates 310
Hepatitis B - Dormant Projects 348
Hepatitis B - Discontinued Products 358
Hepatitis B - Product Development Milestones 359
Appendix 368

List of Tables

Number of Products under Development for Hepatitis B, H1 2016 26
Number of Products under Development for Hepatitis B - Comparative Analysis, H1 2016 27
Number of Products under Development by Companies, H1 2016 29
Number of Products under Development by Companies, H1 2016 (Contd..1) 30
Number of Products under Development by Companies, H1 2016 (Contd..2) 31
Number of Products under Development by Companies, H1 2016 (Contd..3) 32
Number of Products under Development by Companies, H1 2016 (Contd..4) 33
Number of Products under Development by Companies, H1 2016 (Contd..5) 34
Number of Products under Investigation by Universities/Institutes, H1 2016 35
Comparative Analysis by Late Stage Development, H1 2016 36
Comparative Analysis by Clinical Stage Development, H1 2016 37
Comparative Analysis by Early Stage Development, H1 2016 38
Comparative Analysis by Unknown Stage Development, H1 2016 39
Products under Development by Companies, H1 2016 40
Products under Development by Companies, H1 2016 (Contd..1) 41
Products under Development by Companies, H1 2016 (Contd..2) 42
Products under Development by Companies, H1 2016 (Contd..3) 43
Products under Development by Companies, H1 2016 (Contd..4) 44
Products under Development by Companies, H1 2016 (Contd..5) 45
Products under Development by Companies, H1 2016 (Contd..6) 46
Products under Development by Companies, H1 2016 (Contd..7) 47
Products under Development by Companies, H1 2016 (Contd..8) 48
Products under Investigation by Universities/Institutes, H1 2016 49
Hepatitis B - Pipeline by Abivax S.A., H1 2016 50
Hepatitis B - Pipeline by AiCuris GmbH & Co. KG, H1 2016 51
Hepatitis B - Pipeline by AIMM Therapeutics B.V., H1 2016 52
Hepatitis B - Pipeline by Akshaya Bio Inc., H1 2016 53
Hepatitis B - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 54
Hepatitis B - Pipeline by AlphaMab Co., Ltd, H1 2016 55
Hepatitis B - Pipeline by Altimmune, Inc., H1 2016 56
Hepatitis B - Pipeline by Altravax, Inc., H1 2016 57
Hepatitis B - Pipeline by Amarna Therapeutics B.V., H1 2016 58
Hepatitis B - Pipeline by Arbutus Biopharma Corporation, H1 2016 59
Hepatitis B - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016 60
Hepatitis B - Pipeline by Assembly Biosciences, Inc., H1 2016 61
Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016 62
Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 63
Hepatitis B - Pipeline by Benitec Biopharma Limited, H1 2016 64
Hepatitis B - Pipeline by BioDiem Ltd, H1 2016 65
Hepatitis B - Pipeline by Biogenomics Limited, H1 2016 66
Hepatitis B - Pipeline by Biological E. Limited, H1 2016 67
Hepatitis B - Pipeline by BioStar Pharmaceuticals, Inc., H1 2016 68
Hepatitis B - Pipeline by Bolder Biotechnology, Inc., H1 2016 69
Hepatitis B - Pipeline by Bukwang Pharm.Co., Ltd., H1 2016 70
Hepatitis B - Pipeline by CaroGen Corporation, H1 2016 71
Hepatitis B - Pipeline by Celltrion, Inc., H1 2016 72
Hepatitis B - Pipeline by Chimerix, Inc., H1 2016 73
Hepatitis B - Pipeline by ChronTech Pharma AB, H1 2016 74
Hepatitis B - Pipeline by Cocrystal Pharma, Inc., H1 2016 75
Hepatitis B - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016 76
Hepatitis B - Pipeline by CyTuVax B.V., H1 2016 77
Hepatitis B - Pipeline by Dynavax Technologies Corporation, H1 2016 78
Hepatitis B - Pipeline by Ensemble Therapeutics Corporation, H1 2016 79
Hepatitis B - Pipeline by Enyo Pharma S.A.S., H1 2016 80
Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H1 2016 81
Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 82
Hepatitis B - Pipeline by GeneCure LLC, H1 2016 83
Hepatitis B - Pipeline by Gilead Sciences, Inc., H1 2016 84
Hepatitis B - Pipeline by GlaxoSmithKline Plc, H1 2016 85
Hepatitis B - Pipeline by Green Cross Corporation, H1 2016 86
Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H1 2016 87
Hepatitis B - Pipeline by Humabs BioMed SA, H1 2016 88
Hepatitis B - Pipeline by Immunotope, Inc., H1 2016 89
Hepatitis B - Pipeline by Immunovaccine, Inc., H1 2016 90
Hepatitis B - Pipeline by Indian Immunologicals Limited, H1 2016 91
Hepatitis B - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 92
Hepatitis B - Pipeline by ISA Pharmaceuticals B.V., H1 2016 93
Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016 94
Hepatitis B - Pipeline by Johnson & Johnson, H1 2016 95
Hepatitis B - Pipeline by Kineta, Inc., H1 2016 96
Hepatitis B - Pipeline by Kuros Biosciences AG, H1 2016 97
Hepatitis B - Pipeline by Leukocare AG, H1 2016 98
Hepatitis B - Pipeline by LG Life Science LTD., H1 2016 99
Hepatitis B - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 100
Hepatitis B - Pipeline by Mologen AG, H1 2016 101
Hepatitis B - Pipeline by Mucosis B.V., H1 2016 102
Hepatitis B - Pipeline by MultiCell Technologies, Inc., H1 2016 103
Hepatitis B - Pipeline by Panacea Biotec Limited, H1 2016 104
Hepatitis B - Pipeline by Pfenex Inc., H1 2016 105
Hepatitis B - Pipeline by PharmaEssentia Corporation, H1 2016 106
Hepatitis B - Pipeline by Profectus BioSciences, Inc., H1 2016 107
Hepatitis B - Pipeline by Redx Pharma Plc, H1 2016 108
Hepatitis B - Pipeline by REPLICor Inc., H1 2016 109
Hepatitis B - Pipeline by Sanofi Pasteur SA, H1 2016 110
Hepatitis B - Pipeline by SEEK Group, H1 2016 111
Hepatitis B - Pipeline by Sinovac Biotech Ltd., H1 2016 112
Hepatitis B - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 113
Hepatitis B - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H1 2016 114
Hepatitis B - Pipeline by TCM Biotech International Corp, H1 2016 115
Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H1 2016 116
Hepatitis B - Pipeline by TGV-Laboratories, H1 2016 117
Hepatitis B - Pipeline by Theravectys SA, H1 2016 118
Hepatitis B - Pipeline by Tomegavax, Inc., H1 2016 119
Hepatitis B - Pipeline by Transgene SA, H1 2016 120
Hepatitis B - Pipeline by UAB Profarma, H1 2016 121
Hepatitis B - Pipeline by Vaxine Pty Ltd, H1 2016 122
Hepatitis B - Pipeline by Viriom Ltd., H1 2016 123
Hepatitis B - Pipeline by VLP Biotech, Inc., H1 2016 124
Hepatitis B - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 125
Assessment by Monotherapy Products, H1 2016 126
Assessment by Combination Products, H1 2016 127
Number of Products by Stage and Target, H1 2016 129
Number of Products by Stage and Mechanism of Action, H1 2016 132
Number of Products by Stage and Route of Administration, H1 2016 135
Number of Products by Stage and Molecule Type, H1 2016 137
Hepatitis B Therapeutics - Recent Pipeline Updates, H1 2016 327
Hepatitis B - Dormant Projects, H1 2016 365
Hepatitis B - Dormant Projects (Contd..1), H1 2016 366
Hepatitis B - Dormant Projects (Contd..2), H1 2016 367
Hepatitis B - Dormant Projects (Contd..3), H1 2016 368
Hepatitis B - Dormant Projects (Contd..4), H1 2016 369
Hepatitis B - Dormant Projects (Contd..5), H1 2016 370
Hepatitis B - Dormant Projects (Contd..6), H1 2016 371
Hepatitis B - Dormant Projects (Contd..7), H1 2016 372
Hepatitis B - Dormant Projects (Contd..8), H1 2016 373
Hepatitis B - Dormant Projects (Contd..9), H1 2016 374
Hepatitis B - Discontinued Products, H1 2016 375